Winning Stock Forecast: ENDP Returns up to 39.05% in 1 Month as Powerful Agreements Pan Out

“Medicine is the science of uncertainty and an art of probability”

-William Osler

(Source: Pixabay)

Endo International plc is a generics and specialty branded pharmaceutical company. Incorporated on October 31, 2013, the company has three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The company has brands in the U.S. and abroad, including Canada and Latin America.

On June 8, I Know First gave a bullish one month forecast for ENDP. Over that one month period, the stock returned up to 39.05%.

ENDP Price (Source: Yahoo Finance)

<span

Read More

Quick Win by the Algorithm: Corcept Therapeutics Stock Price Rallies with Strong Performance and Insitituional Support

Stock Prediction Quick Win

Read The Full Forecast

TEVA Stock Forecast: Teva Announces Restructuring Plan After Shrank Of $57 Billion

 The article was written by Aline Rzetelna, a Financial Analyst at I Know First

TEVA Stock Prediction

Summary:

  • Why Teva Shrank By $57 billion In Two-And-A-Half Years
  • Teva Announces Restructuring Plan
  • I Know First Forecast for TEVA

Microsoft Stock OutlookRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Stock Price Valeant: Step by Step, Out of the Pit





This article was written by Mingyue Liu, a Financial Analyst at I Know First.

Valeant Pharmaceuticals International: Step by Step, Out of the Pit

"Medicine really matured me as a person because, as a physician, you're obviously dealing with life and death issues, issues much more serious than what we're talking about in entertainment. You can't get more serious than life and death. And if you can handle that, you can handle anything." (Ken Jeong)

Summary:
  • Debt divestiture through debt redemption and non-core business sales
  • Organic growth bolstered by potential launch of new drugs
  • Other tailwinds that may weigh on the company's growth

IBM priceRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Stock Market Outlook Quick Win by the Algorithm: FDA Approval Expedites OMER’s Growth

Quick Win by the Algorithm

Read The Full Forecast

quick win

Alexion Stock Analysis: New Management Will Lead ALXN in a Prosperous Direction

This article was written by Jason Schwartz, a Financial Analyst at I Know First,

Alexion Stock Analysis 

Summary

  • Alexion is best known for the development of Soliris
  • Used to treat patients with PNH and aHUS, both rare medical conditions.
  • Internal investigation results in overhaul of senior management including CEO and CFO
  • Bullish I Know First Forecast for AXLN

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Quick Win by the Algorithm: Positive Outlook for Achillion

Quick Win by the Algorithm

Read The Full Forecast

Pages:12»
  • Get Your Stock Forecast Now